<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020004</url>
  </required_header>
  <id_info>
    <org_study_id>ASC08201502</org_study_id>
    <nct_id>NCT03020004</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II</brief_title>
  <official_title>A Phase 2,Multicenter,Open-Label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis GT1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of
      Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive
      Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Permanently Discontinuing Study Drug(s) Due to an Adverse Event (AE)</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir (DNV) 100mg tablet administered orally twice daily</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>ASC08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100mg tablet administered orally twice daily</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>PegIFN subcutaneous injection at 180 mcg weekly</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>PegIFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) ;

          -  Positive HCV antibody

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or
             host-targeting antivirals for HCV

          -  The liver biopsy methods in the protocol (non-cirrhosis is defined as: Metavir score ˂
             4), or as determined by Fibroscan defined as: ˂ 14.6 kPa. Patients who have not
             obtained a liver biopsy or Fibroscan in the last 1 years will have a study related
             Fibroscan performed in order to confirm the diagnosis

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value &gt; 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease, including but not
             limited to, autoimmune hepatitis, α-1-antitrypsin deficiency, C282Y homozygous
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,
             alcohol-related liver disease, primary biliary cirrhosis, sclerosing cholangitis, and
             porphyria cutanea tarda causing liver pathology or requiring phlebotomy

          -  Patients with a history of liver cell cancer, screening before or screening suspected
             hepatocellular carcinoma (HCC) patients, or imaging studies found suspicious nodules,
             or AFP &gt; 50 ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody
             or HIV antibody at screening

          -  Others as specified in the detailed protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huoling Tang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <results_first_submitted>January 9, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2018</results_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danoprevir</keyword>
  <keyword>SVR12</keyword>
  <keyword>Chinese HCV G1</keyword>
  <keyword>non-cirrhotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Danoprevir,Ritonavir, Peg-IFN,RBV</title>
          <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.
Danoprevir: Danoprevir (DNV) 100mg tablet administered orally twice daily
Ritonavir: Ritonavir 100mg tablet administered orally twice daily
peginterferon alfa-2a: PegIFN subcutaneous injection at 180 mcg weekly
Ribavirin (RBV): Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Danoprevir,Ritonavir, Peg-IFN,RBV</title>
          <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.
Danoprevir: Danoprevir (DNV) 100mg tablet administered orally twice daily
Ritonavir: Ritonavir 100mg tablet administered orally twice daily
peginterferon alfa-2a: PegIFN subcutaneous injection at 180 mcg weekly
Ribavirin (RBV): Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment</title>
        <description>SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Danoprevir,Ritonavir, Peg-IFN,RBV</title>
            <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.
Danoprevir: Danoprevir (DNV) 100mg tablet administered orally twice daily
Ritonavir: Ritonavir 100mg tablet administered orally twice daily
peginterferon alfa-2a: PegIFN subcutaneous injection at 180 mcg weekly
Ribavirin (RBV): Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment</title>
          <description>SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Permanently Discontinuing Study Drug(s) Due to an Adverse Event (AE)</title>
        <time_frame>36 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Danoprevir,Ritonavir, Peg-IFN,RBV</title>
          <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.
Danoprevir: Danoprevir (DNV) 100mg tablet administered orally twice daily
Ritonavir: Ritonavir 100mg tablet administered orally twice daily
peginterferon alfa-2a: PegIFN subcutaneous injection at 180 mcg weekly
Ribavirin (RBV): Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="85" subjects_affected="63" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="69" subjects_affected="58" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Ascletis, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The study has been completed at all study sites for at least 3 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Ascletis Pharmaceuticals Co., Ltd</organization>
      <phone>+86057185389732</phone>
      <email>yicheng.zhao@ascletis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

